Chosa Oncology, CEO and CCO
| Published June 2, 2025

BioStock Investor Pitch: Chosa Oncology

Biotechnology company Chosa Oncology focuses on precision medicine in cancer treatment. The company develops technologies that aim to improve the efficacy and reduce the side effects of platinum-based chemotherapies, such as cisplatin, by identifying which patients are likely to respond to the treatment. They are currently in the process of a so-called hybrid issue and CEO Peter Buhl Jensen and Chief Commercial Officer Claus Frisenberg came to BioStock's studio to present the company.

Watch the presentation with the CEO Peter Buhl Jensen and CCO Claus Frisenberg, in English, below.

BioStock is a news service and does not provide investment advice, does not mediate any investment orders and does not take any responsibility for actions and/or any loss or damage of any kind based on the use of content published on BioStock.se. Instead, each investment decision is made independently by the individual investor. The content of BioStock's news and analyses is independent, but as BioStock's operations are partly financed by companies in the industry, the BioStock website may contain news about companies from which BioStock has received funding.

This material has been prepared for marketing purposes and is not and shall not be considered to constitute a prospectus under applicable laws and regulations. The full terms and conditions of the rights issue and further information about the company have been set out in a prospectus which has been published and published on the said company's website.